AMEX · MTNB
Healthcare · Biotechnology
$0.20
Up+$0.02 (+8.93%)
Updated Aug 22, 2026, 6:11 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
MTNB closed at $0.20 after 21 trading sessions, down 17.65% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $0.1821 | $0.206 | $0.18 | $0.1988 | 832.85K |
| Aug 20, 2026 | $0.207 | $0.207 | $0.178 | $0.1825 | 2.94M |
| Aug 19, 2026 | $0.2048 | $0.2579 | $0.1817 | $0.241 | 9.61M |
| Aug 18, 2026 | $0.2222 | $0.226 | $0.2015 | $0.2037 | 827.51K |
| Aug 17, 2026 | $0.229 | $0.234 | $0.222 | $0.2222 | 616.94K |
| Aug 14, 2026 | $0.2387 | $0.25 | $0.2216 | $0.234 | 2.44M |
| Aug 13, 2026 | $0.2382 | $0.2433 | $0.2307 | $0.233 | 337.38K |
| Aug 12, 2026 | $0.2494 | $0.2494 | $0.2275 | $0.24 | 1.03M |
| Aug 11, 2026 | $0.261 | $0.2749 | $0.2468 | $0.262 | 527.49K |
| Aug 10, 2026 | $0.28 | $0.28 | $0.2565 | $0.269 | 349.7K |
| Aug 7, 2026 | $0.2603 | $0.283 | $0.2496 | $0.283 | 1.16M |
| Aug 6, 2026 | $0.2667 | $0.2748 | $0.2519 | $0.2684 | 304.75K |
| Aug 5, 2026 | $0.2818 | $0.2982 | $0.2615 | $0.275 | 771.39K |
| Aug 4, 2026 | $0.2927 | $0.3213 | $0.27 | $0.2905 | 1.09M |
| Aug 3, 2026 | $0.29 | $0.3145 | $0.2802 | $0.3016 | 1.02M |
| Jul 31, 2026 | $0.32 | $0.32 | $0.2816 | $0.2938 | 2.2M |
| Jul 30, 2026 | $0.285 | $0.3245 | $0.285 | $0.3174 | 14.87M |
| Jul 29, 2026 | $0.26 | $0.44 | $0.26 | $0.2979 | 25.7M |
| Jul 28, 2026 | $0.32 | $0.32 | $0.275 | $0.293 | 7.67M |
| Jul 27, 2026 | $0.38 | $0.43 | $0.311 | $0.332 | 206.25M |
| Jul 24, 2026 | $0.2504 | $0.267 | $0.2312 | $0.2414 | 33.83M |
The latest Smart Investors Daily articles mentioning MTNB.
MTNB research
Company profile and research snapshot.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 31, 2024 | Maxim Group | Hold | — |
| Oct 11, 2023 | BTIG | Buy | — |
| Jan 31, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2020 | Aegis Capital | Buy | — |
| Jan 27, 2020 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Benzinga · Aug 20, 2026
Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-market session. The company's market cap stands at $60.1 million. The company's, Q2 earnings came out yesterday.
Benzinga · Aug 20, 2026
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.
Benzinga · Aug 19, 2026
https://x.com/PatentGrants/status/2090166066538512778https://patentcenter.uspto.gov/applications/18767226/ifw/docs
Benzinga · Aug 7, 2026
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MTNB.
